gemcitabine has been researched along with n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishigaki, Y; Kawakami, K; Kitano, A; Minamoto, T; Motoo, Y; Nakajima, H; Nakamura, Y; Nakaya, N; Sato, I; Shimasaki, T; Takata, T; Takegami, T; Tanaka, T; Tomosugi, N; Zhao, X | 1 |
1 other study(ies) available for gemcitabine and n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea
| Article | Year |
|---|---|
Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Urea; Xenograft Model Antitumor Assays | 2012 |